BioVersys

BioVersys is a multi-asset, clinical-stage biopharmaceutical company focused on the development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant bacteria.

Equities

Equities by Sector

Sectors

Megatrends

Thematics

Latest

Edison explains: The next phase of the obesity market

Edison explains: The cost of insecure infrastructure

Have autos hit the brakes too hard?

Audiovisual

Latest

BlackRock Greater Europe Investment Trust – equity proposition

Corero Network Security – executive interview

Uncovering Trusts – Baker Steel Resources Trust (BSRT): Capturing value along the mining development curve

About Edison

Corporates

Investors

Careers

BioVersys (SIX: BIOV)

Latest News

Latest Insights

BioVersys — Clinical progress, commercial optionality

BioVersys (SIX: BIOV) reports strong H126; FY26 guidance upgraded

BioVersys — Fast Track de-risks BV100’s regulatory pathway

BioVersys (SIX:BIOV) gains FDA Fast Track for BV100

Share Price Chart

Market Data

Sector

Equity Analyst

Key Management

Research

BioVersys – executive interview

BioVersys — Targeting resistant and threatening indications

BioVersys – executive interview

BioVersys — Targeting resistant and threatening indications

Redesigning immunity: The next frontier in immuno-oncology

Edison explains: Investing in health stocks – how policy clarity is opening doors

The CNS renaissance: Innovations are reshaping neurological therapies

Healthcare-focused trusts: A sector on the mend

Outlook for 2024: Life sciences – where has the conviction gone?

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

VolitionRx – Decoding the DNA of cancer

ASCO 2023 key takeaways

Machine learning in drug development

Outlook for 2023: Biotechs remain central to novel drug development

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

Cell and gene therapies

Drug delivery platforms

Oncology ABCs (part three) – thinking outside the box in women’s cancer

Neuroscience comeback

IPO apocalypse

Oncology ABCs (part two) – vaccines: niche no longer

ESG, moving beyond the box tick

Oncology ABCs (part one) – a small-cap biopharma prospectus series

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

Artificial intelligence in drug discovery

Biosynthesis – Taking the cannabinoid market to new heights

Seven things every investor should know about SIGA technologies & biological weapons

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

Edison Exhibits- antibiotic development

The next wave in AMD

The A-B-T of biosimilars- Explaining contemporary life science issues

Cannabinoid Therapies- The coming retail wave

Cannabinoid Therapies- Therapeutics turning a corner

Trial outcomes and value – Explaining contemporary clinical trial issues

Drug pricing – Market access and reimbursement

The diagnostics sector

ASCO 2017

Deutsche Börse Eigenkapitalforum 2014 Research Guide

Edison healthcare quarterly: A boost for allergy immunotherapy

ASX Spotlight Conference – London, 6 March 2014

ASX Small to Mid Caps Conference – London, 7 March 2013

Edison healthcare quarterly: Boom times for US biotech

Edison healthcare quarterly: Crisis? What crisis?

Edison healthcare quarterly: How to please some of the people some of the time